Cytori to Begin Stem Cell Trial for Heart Disease
Cytori's trial, designated as the 'PRECISE' study, will primarily evaluate safety and feasibility in 36 patients with chronic ischemia, a severe form of coronary artery disease. The Company's Celution' stem and regenerative cell processing system will extract and concentrate a patient's cells in the catheterization suite so they are available for the physician to re-inject into damaged heart muscle in about an hour. A variety of clinical functional and imaging endpoints will be assessed in the study. The outcomes of the study will be evaluated after a six month follow up.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.